Editor-in-Chief: Godefridus J. Peters
Journal Rank: 2025 Impact Factor: 7.6 - Q1 (ONCOLOGY); CiteScore 2025: 10.3 - Q1 (Pharmacology)
Median time to first editorial decision: 9 days

Cancer Drug Resistance

Articles

Most Recent | Most Viewed | Most Downloaded

Unveiling the role of UGT enzymes in chemoresistance: a path to enhanced cancer pharmacotherapy

Open Access Original Article DOI: 10.20517/cdr.2026.10 7 Jun 2026
Views: Downloads:
Download PDF

A systematic review and network meta analysis of first-line immunotherapy for advanced urothelial carcinoma

Open Access Meta-Analysis DOI: 10.20517/cdr.2026.22 4 Jun 2026
Views: Downloads:
Download PDF

Fenretinide in cancer therapy and chemoprevention: past, present and future

Open Access Review DOI: 10.20517/cdr.2025.210 4 Jun 2026
Views: Downloads:
Download PDF

Deep spatial proteomics reveals a suppressive immune niche linked to immune evasion in renal cell carcinoma

Open Access Original Article DOI: 10.20517/cdr.2026.27 18 May 2026
Views: Downloads:
Download PDF

Overcoming resistance to anti-PD-1/PD-L1 therapy in cancer

Open Access Review DOI: 10.20517/cdr.2026.12 14 May 2026
Views: Downloads:
Download PDF

Tumor microenvironment-driven resistance to immunotherapy in non-small cell lung cancer: strategies for Cold-to-Hot tumor transformation

Open Access Review DOI: 10.20517/cdr.2025.14 23 Apr 2025
Views: Downloads:
Download PDF

ALK inhibitors in cancer: mechanisms of resistance and therapeutic management strategies

Open Access Review DOI: 10.20517/cdr.2024.25 22 May 2024
Views: Downloads:
Download PDF

NFE2L2 and ferroptosis resistance in cancer therapy

Open Access Review DOI: 10.20517/cdr.2024.123 24 Oct 2024
Views: Downloads:
Download PDF

Coming soon.

For Readers

Add your e-mail address to receive forthcoming Issues of this journal:

Articles Collection
a new scientific initiative designed to foster global dialogue, collaboration, and innovation in cancer drug resistance research.
The 2025 Impact Factor of Cancer Drug Resistance has risen to 7.6, up from 5.2 last year and placing the journal among the top 15% of journals in Oncology.
Q1 in Pharmacology and Cancer Research | #20 in Pharmacology Worldwide
From CAR-T failure to TME reprogramming: exploring immune escape, developmental biology, TME remodeling, and next-generation therapeutic strategies in pediatric malignancies.
Exploring the Future of Cancer Immunotherapy, the Impact of Treg Cell Discovery, and Ethical Considerations in CRISPR Research

Coming soon.

Articles Collection
Cancer Drug Resistance
ISSN 2578-532X (Online)

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/